share_log

Aditxt | 10-Q: Q3 2024 Earnings Report

Aditxt | 10-Q: Q3 2024 Earnings Report

Aditxt | 10-Q：2024财年三季报
美股SEC公告 ·  11/19 06:06

Moomoo AI 已提取核心信息

Aditxt, Inc., a biotech company focused on immune modulation and personalized medicine, reported a net loss of $29,472,886 for the quarter ended September 30, 2024. The company's revenue for the quarter was $6,854, a significant decrease from the $124,486 reported in the same period in 2023. The cost of goods sold was $467,536, contributing to a gross loss of $460,682. Operating expenses included $3,718,804 in general and administrative costs, $491,552 in research and development, and $30,000 in sales and marketing. The company's financial situation raises substantial doubt about its ability to continue as a going concern, with a working capital deficit of $(22,280,585) and cash reserves of $328,596. Aditxt is actively seeking additional funding to continue operations and clinical trials. The company's obligations to secured creditors total approximately $7.7 million, with a weekly payment requirement of $277,800. Aditxt's stock is at risk of being delisted from the Nasdaq due to non-compliance with minimum bid price requirements, which could further impact its financial stability and operations.
Aditxt, Inc., a biotech company focused on immune modulation and personalized medicine, reported a net loss of $29,472,886 for the quarter ended September 30, 2024. The company's revenue for the quarter was $6,854, a significant decrease from the $124,486 reported in the same period in 2023. The cost of goods sold was $467,536, contributing to a gross loss of $460,682. Operating expenses included $3,718,804 in general and administrative costs, $491,552 in research and development, and $30,000 in sales and marketing. The company's financial situation raises substantial doubt about its ability to continue as a going concern, with a working capital deficit of $(22,280,585) and cash reserves of $328,596. Aditxt is actively seeking additional funding to continue operations and clinical trials. The company's obligations to secured creditors total approximately $7.7 million, with a weekly payment requirement of $277,800. Aditxt's stock is at risk of being delisted from the Nasdaq due to non-compliance with minimum bid price requirements, which could further impact its financial stability and operations.
Aditxt公司是一家专注于免疫调节和个性化医疗的生物技术公司，报告截至2024年9月30日的季度净亏损为29,472,886美元。该季度公司的营业收入为6,854美元，较2023年同期的124,486美元大幅下降。营业成本为467,536美元，导致毛亏损为460,682美元。营业费用包括3,718,804美元的总务和行政费用、491,552美元的研发费用以及30,000美元的销售和市场费用。公司的财务状况让人对其持续经营的能力产生重大疑虑，流动资本赤字为(22,280,585)美元，现金储备为328,596美元。Aditxt正在积极寻求额外资金以继续运营和临床试验。该公司对担保债权人的债务总额约为770万，周支付要求为277,800美元。由于未能满足最低买盘价格要求，Aditxt的股票面临被纳斯达克退市的风险，这可能进一步影响其财务稳定性和运营。
Aditxt公司是一家专注于免疫调节和个性化医疗的生物技术公司，报告截至2024年9月30日的季度净亏损为29,472,886美元。该季度公司的营业收入为6,854美元，较2023年同期的124,486美元大幅下降。营业成本为467,536美元，导致毛亏损为460,682美元。营业费用包括3,718,804美元的总务和行政费用、491,552美元的研发费用以及30,000美元的销售和市场费用。公司的财务状况让人对其持续经营的能力产生重大疑虑，流动资本赤字为(22,280,585)美元，现金储备为328,596美元。Aditxt正在积极寻求额外资金以继续运营和临床试验。该公司对担保债权人的债务总额约为770万，周支付要求为277,800美元。由于未能满足最低买盘价格要求，Aditxt的股票面临被纳斯达克退市的风险，这可能进一步影响其财务稳定性和运营。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间